Disclaimer

The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Day

January 7, 2025
PRESS RELEASE NON-REGULATED INFORMATION 7 January 2025, 07:00 am CET alfapump® system is effective in controlling ascites in decompensated cirrhosis with recurrent or refractory ascites by reducing or even eliminating the need for therapeutic paracentesis[1] Reduction was associated with a significant improvement in quality of life[1][2] 10 additional good health days per month in these patients[1]...
Read More

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES